An observational study in Inflammatory Bowel Disease (IBD), Crohn Disease and Ulcerative Colitis (Disorder), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 7 under way, 2 of them phase 3. Inflammatory Bowel Diseases · Assistance Publique - Hôpitaux de Paris.
Among the 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 13th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →5 of the 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–74 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
Assistance Publique - Hôpitaux de Paris
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 240 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 135 across the 8 interventional studies, 220 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
1 of the studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04997733Phase 3Assistance Publique - Hôpitaux de ParisFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal | 2027-05-22 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Inflammatory Bowel Diseases by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Inflammatory bowel diseases (IBD) are long-term conditions affecting more than 250,000 people in France. They typically begin in young adults and are characterized by flare-ups interspersed with periods of remission. The impact of these diseases goes beyond digestive symptoms, with fatigue present in 50 to 80% of cases. The overall effect on health leads to a decline in quality of life and work productivity. Therapeutic management relies on long-term immunosuppressive treatments aimed at inducing prolonged remission. While therapeutic management has become more complex with an increasing number of available treatments, evaluating the effectiveness and tolerance of these treatments requires a multimodal approach, including therapeutic education and specific follow-up based on the patient's profile and treatment, with the goal of comprehensive care and precision medicine.
Recently, multimodal day hospitalizations have been developed, particularly in response to the recent evolution of treatment administration routes toward subcutaneous or oral forms. In 2022, the gastroenterology and nutrition department of Saint Antoine Hospital, which follows 3,500 patients with CIBD, created a multimodal day hospital (DH) (four interventions) dedicated to patients treated with biologics and Janus kinase inhibitors. In a single session, this approach systematically combines (1) specific biological tests, especially pharmacokinetics, (2) a consultation with a gastroenterologist, (3) a consultation with a therapeutic education nurse, (4) and, depending on the identified needs of the patients, a dietary workshop or fatigue management session; a specialized dermatology or rheumatology consultation; and an ultrasound of the intestinal wall.
The goal of this study is to assess the benefits of a multimodal day hospital on the management and skills of patients with IBD.
This is a non-interventional cohort study. Patients will be included over a 6-month period during a scheduled multimodal day hospital visit as part of their care. Before their day hospital appointment, patients will receive an information sheet explaining the research process.
M0 Inclusion:
Patients who agree to participate in the research will receive evaluation questionnaires to be completed online, which include:
Day of DH:
Upon arrival at the multimodal day hospital, if the questionnaires have not been completed in advance, patients will be offered the opportunity to complete them during their visit, with an estimated duration of 30 minutes.
M1 (4 Weeks Post-DH):
Four weeks after the day hospital visit, patients will receive an email with a link to complete the questionnaires again (adherence, knowledge of their disease, fatigue, dietary questionnaire, and productivity). If the questionnaires are not completed, a reminder email will be sent 3 days and 1 month after the due date. If there is no response, a phone call will be scheduled 1 week after the initially planned date by the clinical research technician. Questionnaires can be filled out up to 8 weeks after inclusion.
M6 (6 Months Post-DH):
Six months after the day hospital visit, patients will again receive an email with a link to complete the questionnaires (adherence, knowledge of their disease, fatigue, dietary questionnaire, and productivity). A reminder email will be sent 3 days and 1 month after the due date if there is no response. If there is still no response, a phone call will be made 1 week after the initially scheduled date by the clinical research technician. Questionnaires can be completed up to 7 months after inclusion.
Between M0 and M1:
Treatment optimization and the update of the vaccination schedule will be recorded in the patient's electronic health record.
Study Participation End:
Participation in the study will conclude after the completion of the questionnaires, no later than 7 months after inclusion Statistical analysis The analysis will be performed using SAS v9.4 software (or a later version) by the URC-Est at the end of the study after the database freeze. A detailed statistical analysis plan will be written before the database freeze. A flow chart will be created.
The patient profile at inclusion will be described, including comorbidities, characteristics of the IBD (such as clinical and biological activity at the time of the day hospital visit), and treatments. The day hospital process will be evaluated, including the number of patients per session and the type of interventions performed.
Qualitative variables will be described by their frequency and count, while quantitative variables will be described by their mean and standard deviation or by their median and interquartile range, depending on their distribution.
Analysis of the Primary Endpoint The proportion of patients with an improvement in their skills at one month or an improvement in the management of their disease will be calculated. The proportion of patients with improvement in each of the two groups of criteria will also be calculated.
Analysis of Secondary Endpoints Secondary endpoints will be measured by the proportion of patients showing improvement for each individual item. The total number of items with improvement per patient will also be evaluated, as well as the proportion of patients with access to practitioners such as a dietitian specialized in IBD, a rheumatologist, or a dermatologist outside the day hospital, based on the dedicated questionnaire.
A logistic regression will be conducted to identify the predictors of improvement in patient skills or disease management, based on patient characteristics, IBD features, and treatments.
Patients with ulcerative colitis and Crohn's disease for more than 3 months, with a confirmed diagnosis according to European guidelines, being followed in the gastroenterology department at Saint Antoine Hospital and eligible for a multimodal day hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Proportion of patients with a change in their skills at one month or a modification in the management of their disease
For this study, the benefit of the multimodal Day Hospital (DH) will be evaluated through two groups of criteria: * The criteria of the "Improvement of Patient Skills" group, assessed at the time of day hospitalization and one month later. * The criteria of the "Improvement in Patient Management" group, assessed at the time of day hospitalization. The multimodal DH will be considered beneficial if at least one of these two groups of criteria is met.
Time frame: 1 month
self-declared drug adherence rate
Evaluation of skill-related criteria at the 6-month mark self-declared drug adherence rate: scale from 0 to 100 A threshold below 80% defines non-compliant patients. A relative increase of 20% will be considered a significant improvement.
Time frame: 1 and 6 month
Percentage of patients requiring a treatment discontinuation
Time frame: 1 and 6 month
Percentage of patients requiring changes in treatment dosages
Time frame: 1 and 6 month
The proportion of patients showing improvement for each individual item.
Time frame: 1 and 6 months
The total number of improved criteria per patient.
Time frame: 1 and 6 months
The proportion of patients with access to practitioners such as a dietitian specialized in IBD, a rheumatologist, or a dermatologist, outside of the Day Hospital (DH)
Time frame: 1 and 6 months
IBD-KID2 score
Understanding of disease and treatment based on the IBD-KID2 (inflammatory bowel disease knowledge inventory device) score, comprising 13 questions An absolute increase in score of 3 units will be considered a significant improvement
Time frame: 1 and 6 month
SLQF score for SLFQ Dietary Behavior Change
Patients are categorized into four knowledge categories: insufficient, problematic, sufficient, or excellent, based on respective scores of 0-25, 25-33, 33-42, and 42-50. Any move to a higher category will be considered a significant improvement.
Time frame: 1 and 6 month
Change in fatigue behaviors assessed using the Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F)
An absolute increase in score of 4 units will be considered a significant improvement
Time frame: 1 and 6 month
Work Productivity and Activity Impairment Questionnaire in Crohn's disease (WPAI:CD)
Change in work effectiveness behaviors assessed by the Work Productivity and Activity Impairment Questionnaire in Crohn's disease (WPAI:CD) An absolute increase in score of 20 units will be considered a significant improvement.
Time frame: 1 and 6 month
Work Productivity and Activity Impairment Questionnaire in in Ulcerative Colitis (WPAI:UC)
Change in work Productivity and Activity Impairment Questionnaire in Ulcerative Colitis (WPAI:UC) An absolute increase in score of 20 units will be considered a significant improvement.
Time frame: 1 and 6 month
Plan to share: No — The questionnaires will be completed directly by the patients using an electronic platform accessible via the Internet (e-CRF Cleanweb - Telemedicine SA, with the "ePro" feature), developed by URCEST in collaboration with the coordinating investigator. This method of data collection was chosen to facilitate the completion process and streamline the questionnaire flow. A report of anonymized aggregated data at the end of the study will be published. No individual participant data will be available.
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Feb 2026, 5 months later.
Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 5 months is below that.
Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →